替米沙坦和缬沙坦治疗原发性高血压的临床效果及最小成本分析  

Analysis of clinical effect and minimum cost of telmisartan and valsartan treating primary hypertension

作　　者：潘开瑞[1] 

机构地区：[1]河南中医学院第一附属医院药学部,郑州450000

出　　处：《中国当代医药》2015年第7期124-126,共3页China Modern Medicine

摘　　要：目的比较替米沙坦和缬沙坦治疗原发性高血压的临床效果和经济学效果。方法将148例轻中度原发性高血压患者随机分成两组,治疗组(A组,n=74例)给予替米沙坦40 mg/d,对照组(B组,n=74例)给予缬沙坦80 mg/d,早餐后顿服,疗程为8周。并运用药物经济学的最小成本分析方法评价两种药物的经济学效果。结果两组均能有效降压(P<0.05或P<0.01),A组的总有效率为97.30%,B组为90.54%,两组比较差异无统计学意义(P>0.05)。治疗期间两组均未见明显不良反应。A组治疗总费用为1076.04元,B组治疗总费用为1324.24元,A组每位患者可节省247.6元。结论两组药物治疗原发性高血压具有相似临床的效果,从经济学角度来看替米沙坦更具优势。Objective To compare the clinical effect and economics effect of telmisartan and valsartan treating primary hypertension. Methods 148 patients with mild-moderate primary hypertension were randomly divided into the two groups.In the treatment group （the group A）,40 mg/d for telmisartan was provided,while in the control group （the group B）,80 mg/d for valsartan was used and taken at a draught after breakfast.The course of treatment lasted 8 weeks.The e-conomic effect of the two drugs were evaluated by minimum cost analysis of pharmacoeconomics. Results blood pres-sure in the two groups was both decreased effectively （P〈0.05 or P〈0.01）.The total effective rate in the group A was 97.30%,while in the group B, it was 90.54%,and there was no statistical difference （P〉0.05）.There was no obvious ad-verse reaction occurred in the two groups during treatment.The total cost in the group A was 1076.04 yuan,while in the group B,it was 1324.24 yuan.Every patient in the group A could save 247.6 yuan. Conclusion The two drugs have sim-ilar clinical effect on treating primary hypertension.From economics point of view,telmisartan is better.

关 键 词：替米沙坦 缬沙坦 原发性高血压 最小成本分析 

分 类 号：R544.1[医药卫生—心血管疾病]